U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Prescription Dispensing Laboratories Inc. - 579286 - 02/18/2022
  1. Warning Letters

CLOSEOUT LETTER

Prescription Dispensing Laboratories Inc. MARCS-CMS 579286 —

Delivery Method:
VIA Electronic Mail
Product:
Drugs
Recipient:
Recipient Name
Raymond L. Solano
Recipient Title
President
Prescription Dispensing Laboratories Inc.

101 Commercial Parkway
Cedar Park, TX 78613
United States

Rsolano@pdlabs.net
Issuing Office:
Division of Pharmaceutical Quality Operations II

United States

Mr. Solano:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [Case # 579286; Dated: July 30, 2019]. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

If you have questions regarding the contents of this letter, you may contact John Diehl via phone at 214-253-5288 or email at john.diehl@fda.hhs.gov.

Sincerely,
/S/
John W. Diehl, M.S
Director, Compliance Branch
Office of Pharmaceutical Quality Operations, Division II

Back to Top